Stock Ratings / Health Care / ANL / insiders

IMMX (33) LXRX (39) ABUS (22) BCAX (45) ⌘ Pro Terminal →

Adlai Nortye Group Ltd. (ANL) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

Q: Are ANL insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies ANL leadership and institutional positioning as: BALANCED INSTITUTIONAL POSITIONING.

$10.28 +0.78% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Adlai Nortye Group Ltd. (ANL) carries a Roarable Rating of D+ (Sell) with 52/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ • SELL / AVOID Cap $662.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-2.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ANL)Realized 20D OHLCV Swing Band: ±12.5%

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

ANL Smart-Money Thermometer: BALANCED INSTITUTIONAL POSITIONING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (ANL)

No recent open-market Form 4 cluster sales or emergency dumps flagged on ANL. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ANL)

✓Walkthrough of ANL's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ANL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -27.96%▼ SUPPORT BREAKDOWN

2026-10-30O $10.11H $10.28L $9.36C $10.28VOL 262.1K

RES: $18.85SUP: $16.52SMA50: $13.82SMA200: $11.39

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ANL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ANL Butterfly Map → + Track ANL →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ANL today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ANL. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ANL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ANL)

Health Care Rank #320 of 1016 ⚔️ IMMX vs ANL Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ANL vs. IMMX, LXRX, ABUS, BCAX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Adlai Nortye Group Ltd. (ANL) ranks #320 by composite RQD confidence (52/100, grade D+) and #405 by equity capitalization ($662.0M). Within this direct 5-issuer industry benchmark cohort, ANL leads on earnings valuation at N/A trailing P/E, while LXRX leads on capital efficiency and profitability with -31.5% ROIC and 96.0% gross margin. ANL currently leads its immediate peer cohort in composite quantitative strength at 52/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ANL ACTIVE Adlai Nortye Group Ltd.	D+	52/100	—	—	—	+0.78%	$662.0M	Benchmark Subject
IMMX Immix Biopharma Inc.	E	33/100	—	—	-35.0%	-1.78%	$661.6M	/immx-vs-anl →
LXRX Lexicon Pharmaceuticals Inc.	D-	39/100	—	96.0%	-31.5%	-0.34%	$658.5M	/lxrx-vs-anl →
ABUS Arbutus Biopharma Corporation	E	22/100	—	—	-35.0%	-0.93%	$656.0M	/abus-vs-anl →
BCAX Bicara Therapeutics Inc.	D	45/100	—	—	-35.0%	-0.31%	$643.9M	/bcax-vs-anl →

2. ANL Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Adlai Nortye Group Ltd. (ANL) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $662.0M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. ANL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ANL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Adlai Nortye Group Ltd. (NASDAQ: ANL) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 52/100 at a spot price of $10.28 (+0.78% 1D, market cap $662.0M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, ANL ranks #320 in composite RQD confidence.

How does ANL compare to IMMX and LXRX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ANL carries a Roarable D+ (52/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, IMMX (Immix Biopharma Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $661.6M) and LXRX (Lexicon Pharmaceuticals Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -31.5%, cap $658.5M). Among the 5-stock peer group, ANL leads on earnings multiple (N/A) while LXRX leads on capital efficiency (-31.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ANL?

For Adlai Nortye Group Ltd. (ANL), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #320 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ANL trading relative to its 50-day, 200-day, and 52-week technical levels?

ANL last traded at $10.28 (+0.78% on volume of 44,562 shares), positioning the stock -25.62% below its 50-day simple moving average ($13.82) and -9.75% below its 200-day simple moving average ($11.39). Across its 52-week range of $0.88 to $17.25, ANL sits at the 57.4% percentile with a 14-day RSI of 31.6 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($9.00 to $11.56).

ANL Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are ANL insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies ANL leadership and institutional positioning as: BALANCED INSTITUTIONAL POSITIONING.

Direct Sub-Reports: ANL RQD Cockpit ANL 12M Forecast ANL Earnings & Move ANL Dividends & DRIP ANL Insiders & 13F ANL Whale Options ANL Profit Sankey ANL News & Why